News

On Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Hympavzi ... FDA Approves Pfizer's Second Hemophilia Drug With Six Months. Vandana Singh . Mon, Oct 14, 2024, 7:35 AM 2 min read.
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors Published Oct 11, 2024 1:23pm EDT ...
Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder, as well as the first hemophilia drug to offer a once-weekly treatment ...
Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain hemophilia patients. The drug will be marketed under the trade name Hympavzi.
FDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And Adolescents October 11, 2024 — 11:04 pm EDT Written by RTTNews.com for RTTNews -> ...
Pfizer has several programs investigating treatments for people living with hemophilia. In April, the FDA approved Pfizer’s Beqvez , a one-time gene therapy for patients with hemophilia B.
The Food and Drug Administration on Friday approved a new kind of medicine for hemophilia, clearing Pfizer’s Hympavzi for people with either the “A” or “B” forms of the inherited ...
The US Food and Drug Administration on Tuesday approved Hemgenix, a new drug to treat hemophilia. Manufacturer CSL Behring set the price at $3.5 million per treatment, making it the most expensive ...
On Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients ...
FDA approves Pfizer’s Hympavzi for routine prophylaxis in hemophilia A and B patients, offering a once-weekly dosing via auto-injector pen. Phase 3 trial showed Hympavzi reduced bleeding rates ...